BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
bridgebio pharma股价上涨，因公司宣布FDA批准Attruby用于治疗ATTR-Cm的成年人。此外，HC Wainwright维持对该股的买入评级，并将其价格目标从43美元上调至49美元。
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
bridgebio pharma的股票在公司宣布FDA批准Attruby用于治疗成人ATTR-Cm后上涨。此外，HC Wainwright维持了对该股票的买入评级，并将其目标价格从43美元提高到49美元。
资讯热榜
更新时间